Related Experiment Video
Updated: Jun 28, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023
A clinical study of multiple sclerosis patients treated with betaferon
Maria G Manova1, Ivanka I Kostadinova, Valentin Chr Akabaliev
1Department of Neurology, Medical University, Plovdiv, Bulgaria.
Unlabelled:
We conducted an open prospective randomized study of 58 multiple sclerosis patients who received Betaferon in a dose of 8 MIU every other day for 2 years.
Aim:
To assess the effect of Betaferon treatment depending on the number of relapses in the previous 2 years and the stage of neurological deficit at baseline.
Inclusion Criteria:
clinically definite and MRI-confirmed multiple sclerosis (MS), relapsing-remitting course, at least one relapse 2 years before the study; age 18-50 years; neurological deficit scoring--between 1.0-5.0 steps. According to initial EDSS stage, two groups were formed: group A (32 patients with EDSS score < 2.5 steps) and group B (26 patients with EDSS score > or = 3.0 steps). According to the number of relapses in the last 2 years patients were assigned to group C (29 persons with 1 relapse) and group D (29 persons with > or = 2 relapses).
Results:
Betaferon therapy effectively reduced relapse frequency in all groups. The severity of disability was significantly reduced in younger patients and in patients with milder neurological deficit at baseline. Regression analysis showed strong correlation between therapeutic improvement and baseline severity of disability.
Conclusions:
The obtained results suggest that Betaferon can be used to treat patients with low score of neurological deficit, in an early stage of the disease.
Related Concept Videos
Multiple Sclerosis l: Introduction
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Single Versus Multiple Dose Studies
